Navigation Links
Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
Date:3/11/2008

SILVER SPRING, Md., March 11 /PRNewswire-USNewswire/ -- In a boost to HIV prevention research, Merck & Co., Inc., has agreed to provide a royalty-free license to the non-profit International Partnership for Microbicides (IPM) to develop a novel antiretroviral compound for use as a potential vaginal microbicide.

The compound, called L'644, is a member of a class of antiretroviral molecules known as gp41 fusion inhibitors, which inhibit HIV infection by preventing the virus from fusing with the surface of target cells, an early step in the HIV infection process, potentially representing a novel way to block infection.

This announcement follows a similar agreement with Merck that granted IPM a royalty-free license in 2005 to develop another compound, L'167/CMPD167, which belongs to the class of molecules known as CCR5 blockers.

Microbicides are products, such as gels or films, that could be applied vaginally to prevent HIV transmission during vaginal intercourse. IPM is also developing other delivery methods, such as long-lasting vaginal rings that would release the drug gradually over time.

"Merck deserves recognition for its exemplary commitment to HIV prevention research," says Dr. Zeda Rosenberg, CEO of the International Partnership for Microbicides. "This arrangement for L'644 helps IPM pursue development of compounds that target HIV at many points in the virus's lifecycle. We're working toward the day when millions of women around the world will have access to safe and effective microbicides -- and partnerships like this will help us get there."

Preclinical research conducted by Merck suggests that L'644 is a potent HIV fusion inhibitor that is able to block infection of T cell targets in laboratory settings. For this reason there is a strong scientific rationale for evaluating its potential as an anti-HIV microbicide. Under the terms of the agreement, Merck grants IPM full royalty-free rights to develop L'644 a
'/>"/>

SOURCE International Partnership for Microbicides
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... LONDON , Aug. 20, 2014 Reportbuyer.com ... Global Cardiac Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... Cardiac Defibrillators in US$ Million by the following Product ... provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
Breaking Medicine Technology:Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20Global Market Report of Pralmorelin 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... WASHINGTON, Oct. 31 The following is being,issued by ... will hold a news conference about the lawsuit it ... Agriculture (USDA),to prevent the agency from allowing into the ... cattle over 30 months (OTM) of age,scheduled to begin ...
... Vice President of Scientific Affairs Dr. Randy Huffman ... Fund report, slated for,release October 31. Dr. Huffman ... WCRF,s 9:30 a.m. press conference., The American ... largest,association representing U.S. meat and poultry packers and ...
Cached Medicine Technology:R-CALF United Stockgrowers of America: 'Fighting for the U.S. Cattle Producer' 2
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
(Date:8/20/2014)... amygdala stimulates stress responses in adults, researchers at ... found that the amygdala has an inhibitory effect ... nonhuman primates. , The results are published this ... The amygdala is a region of the brain ... situations and learning about threats. Alterations in the ...
(Date:8/20/2014)... 2014 (HealthDay News) -- New research reveals that, long ... the global spread of the infectious disease known as ... in Africa to seals and sea lions, who then ... years ago, according to an international team of researchers. ... rise again worldwide. This study and further research will ...
(Date:8/20/2014)... New York, US (PRWEB) August 20, 2014 ... advocate, market access, governmental and physician stakeholders networks ... Europe, Asia-Pacific, Latin America, US, Canada, and Emerging ... view into Heartbeat Experts’ perspectives on stakeholder management ... highlighted several new immunotherapy and targeted therapy investigational ...
(Date:8/20/2014)... TX (PRWEB) August 20, 2014 The ... Surgery (ACPS), has expanded its presence throughout Houston to ... Mann Eye Institute and Laser Center building. ACPS plastic ... natural step forward for ACPS, which has risen to ... plastic surgery practices in the state since its establishment ...
Breaking Medicine News(10 mins):Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2
... significantly decreases their ability to regulate blood-sugar levels and ... at the University of Chicago Medical Center in the ... of Science, available online as soon as Dec. 31, ... is thought to be the most restorative sleep stage, ...
... Alcohol and Drug Addiction ... Services Boards Merge, CANTON, Ohio, Dec. 31 ... Community Mental Health,Board and the Alcohol and Drug Addiction Services Board of ... Recovery Services Board,of Stark County., "The combined Board will create a ...
... you love and seek out support from friends, experts advise ... many Americans over 50 will resolve to start a new ... Aging offers tips for helping to keep that resolve: ... on starting an exercise program and to find out if ...
... YORK, Dec. 31 The New Year ... finally lose those excess pounds in a ... to this report from GlaxoSmithKline at:, http://media.medialink.com/WebNR.aspx?story=34274 ... audio, text, graphics and,photos for free and ...
... everyone uncork a merry celebration , , MONDAY, Dec. 31 (HealthDay ... of bubbly to celebrate the New Year, make sure you ... of Ophthalmology. , "A bottle of champagne can be ... popping the cork," Dr. Wayne Bizer, a clinical correspondent for ...
... 31 Ardea Biosciences,Inc. (Nasdaq: RDEA ) ... Agency (MHRA) in the United Kingdom has authorized ... non-nucleoside reverse,transcriptase inhibitor (NNRTI), in patients with human ... "There is a clear unmet need for new ...
Cached Medicine News:Health News:Lack of deep sleep may increase risk of type 2 diabetes 2Health News:Lack of deep sleep may increase risk of type 2 diabetes 3Health News:Combined Boards Provide Better Care to More Clients More Efficiently 2Health News:Make That New Year's Fitness Resolution Stick 2Health News:See to It That New Year's Eve Is Safe 2Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 2Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: